Bit Bio
Business Services · United Kingdom · 51-200 Employees
View Company Info for Free
Overview
Headquarters
The Dorothy Hodgkin Building Babraham Re...Phone Number
+44 1223787297Website
bit.bioRevenue
$37 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
2
1
1
About Bit Bio
bit.bio is a synthetic biology company providing human cells for research, drug discovery and cell therapy. The company applies a patented safe harbour gene-targeting approach (opti-ox; Pawlowski 2017) to inducibly express transcription factor combinations that reprogram human induced pluripotent stem cells (iPSCs) into highly defined and mature human cell types.Explore more
Bit Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Bit Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Bit Bio has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Bit Bio
Check out if Bit Bio is spiking on competitors!
Bit Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Bit Bio recently announced quarterly report
Click to see if Bit Bio had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Bit Bio has new funding data
Product Launch: Get notified when Bit Bio launches new products
Recommended Actions
Find VP level buyers at Bit Bio
Find 3 more new buyers
Compare Similar Companies to Bit Bio
Compare insights from companies similar to Bit Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Bit Bio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Bit Bio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Bit Bio.
Bit Bio financials insights
Gather financial insights about Bit Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Angel/Seed
$471K
2020
Series A
$41.5M
2021
Series B
$103M
2024
Other Financing Round
$30M
Private Equity
$30M
2026
Series C
$50M
Bit Bio Tech Stack
A closer look at the technologies used by Bit Bio
Most Recent Scoops
Hiring Plans
Bit Bio has more open roles in Sales than it has had at any time in the past 9 months. Areas of expertise include: International Sales, Technical Sales, Sales Planning, Sales Process, and Cross-Selling.
Hiring Plans
Open Position
Open Position
Open Position
Open Position
Bit Bio News & Media
bit.bio Publishes 2025 Sustainability Report
ioCells™ portfolio of human iPSC-derived products accelerate the global shift from animal testing to human-relevant research models Platinum Green Impact Award and new lab efficiency protocols deliver measurable, year-on-year sustainability improvements Male and female donor–derived cell...bit.bio Launches ioTracker Cells Range at SLAS 2025, Adding New Visualisation Functionality to Human iPSC-derived Cell Types
Researchers can easily track and isolate bit.bio's consistent, defined, and scalable human iPSC-derived cells for the first time, opening up new applications in neurodegenerative drug discovery. ioTracker Cells, the new range within bit.bio's ioCells portfolio, deliver added visualisation...bit.bio Launches ioTracker Cells Range at SLAS 2025, Adding New Visualisation Functionality to Human iPSC-derived Cell Types
Researchers can easily track and isolate bit.bio's consistent, defined, and scalable human iPSC-derived cells for the first time, opening up new applications in neurodegenerative drug discovery. ioTracker Cells, the new range within bit.bio's ioCells portfolio, deliver added visualisation...bit.bio Raises $30 Million Led by M&G Investments to Focus on Tools for the Research, Drug Discovery and Cell Therapy Markets
Jonathan Milner Appointed Interim CEO; Mark Kotter Assumes Vice Chairman Role as Company Expands Board with Distinguished Biotech Leaders CAMBRIDGE, United Kingdom, Dec. 16, 2024 /PRNewswire/ -- bit.bio, the global leader in cell programming technology, today announced the successful...
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Bit Bio
Sign Up For FreeTo access detailed company insights
bit.bio is a synthetic biology company providing human cells for research, drug discovery and cell therapy. The company applies a patented safe harbour gene-targeting approach (opti-ox; Pawlowski 2017) to inducibly express transcription factor combinations that reprogram human induced pluripotent stem cells (iPSCs) into highly defined and mature hu... Read More
